Ntv Asset Management buys $2,269,806 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Ntv Asset Management scooped up 1,222 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 33,903 shares of AbbVie Inc which is valued at $2,269,806.AbbVie Inc makes up approximately 0.83% of Ntv Asset Management’s portfolio.

Other Hedge Funds, Including , Norinchukin Bank The reduced its stake in ABBV by selling 4,166 shares or 1.92% in the most recent quarter. The Hedge Fund company now holds 213,359 shares of ABBV which is valued at $14,284,385. AbbVie Inc makes up approx 0.33% of Norinchukin Bank The’s portfolio. Princeton Alpha Management Lp sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 44,821 shares of ABBV which is valued $2,982,389. Jackson Grant Investment Advisers sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 29,651 shares of ABBV which is valued $1,972,978.Advisory Services Network reduced its stake in ABBV by selling 118 shares or 3.06% in the most recent quarter. The Hedge Fund company now holds 3,735 shares of ABBV which is valued at $242,402. AbbVie Inc makes up approx 0.05% of Advisory Services Network’s portfolio.Rothschild Investment Corp Il reduced its stake in ABBV by selling 4,315 shares or 2.05% in the most recent quarter. The Hedge Fund company now holds 205,821 shares of ABBV which is valued at $13,133,438. AbbVie Inc makes up approx 1.61% of Rothschild Investment Corp Il’s portfolio.

AbbVie Inc opened for trading at $67.47 and hit $68.1239 on the upside on Monday, eventually ending the session at $67.39, with a gain of 0.30% or 0.2 points. The heightened volatility saw the trading volume jump to 52,15,360 shares. Company has a market cap of $109,747 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *